Last updated: July 31, 2026
Perforomist is the U.S. brand for formoterol fumarate inhalation solution, a nebulized long-acting beta2-adrenergic agonist (LABA) used twice daily for maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. The product is approved for maintenance therapy, not for acute relief of worsening respiratory symptoms or asthma monotherapy.
Perforomist has an established clinical profile but limited growth prospects as a standalone brand. Its market position is constrained by generic formoterol inhalation solution, competing nebulized long-acting bronchodilators, combination inhalers, and broader migration toward single-inhaler maintenance therapy.
What is Perforomist and how does it work?
Perforomist contains formoterol fumarate, a selective long-acting beta2-adrenergic agonist. Each unit-dose vial contains 20 micrograms of formoterol fumarate in 2 mL of inhalation solution. The prescribed dose is one vial administered by nebulization twice daily, approximately 12 hours apart.[1]
Formoterol activates beta2 receptors in bronchial smooth muscle, increasing intracellular cyclic adenosine monophosphate and producing bronchodilation. Its onset is relatively rapid for a LABA, but its regulatory role in Perforomist is maintenance treatment rather than rescue therapy.
FDA-approved indication and limitations
| Regulatory attribute |
Perforomist status |
| Active ingredient |
Formoterol fumarate |
| Dosage form |
Inhalation solution for nebulization |
| Strength |
20 mcg per 2 mL vial |
| Route |
Oral inhalation through a standard jet nebulizer |
| Indication |
Long-term, twice-daily maintenance treatment of bronchoconstriction in COPD |
| Acute rescue use |
Not indicated |
| Asthma use |
Not approved as monotherapy |
| Original U.S. approval |
2007 |
| Reference product |
NDA 021744 |
| Current commercial category |
Mature branded and generic nebulized LABA |
The FDA label warns against use in acute bronchospasm and identifies LABA-related risks including paradoxical bronchospasm, cardiovascular effects, hypokalemia, hyperglycemia and worsening narrow-angle glaucoma.[1]
What clinical trials supported Perforomist approval?
The pivotal Perforomist program evaluated lung-function improvement, symptom control and safety in patients with COPD. The principal endpoint was generally change in forced expiratory volume in one second (FEV1), with additional assessments of peak expiratory flow, rescue medication use and COPD symptoms.
Pivotal efficacy evidence
In controlled trials, formoterol fumarate inhalation solution improved FEV1 compared with placebo. Bronchodilation began shortly after administration and was maintained over the 12-hour dosing interval in the target COPD population.[1]
The approval package was directed at maintenance bronchodilation rather than reduction of COPD exacerbations as a primary outcome. This distinction matters commercially: Perforomist provides sustained airway opening, but it does not occupy the same clinical or reimbursement position as products supported by extensive exacerbation-reduction data.
Safety findings
The main adverse reactions reported in the clinical program included:
- Diarrhea
- Nausea
- Dry mouth
- Headache
- Dizziness
- Insomnia
- Tremor
- Muscle cramps
- Palpitations
As with other LABAs, the safety profile includes class-related cardiovascular and metabolic risks. The product is generally used in patients who require regular bronchodilation and who may have difficulty generating sufficient inspiratory flow for a dry-powder inhaler.
Are there active Perforomist clinical trials?
No major late-stage clinical development program is associated with Perforomist as a branded product. The principal regulatory and commercial questions have shifted from initial efficacy to generic substitution, real-world COPD management, nebulizer use and comparative effectiveness.
ClinicalTrials.gov contains studies involving formoterol, nebulized bronchodilators and COPD treatment, but these studies should not be treated as Perforomist registration trials unless the protocol identifies Perforomist or its specific inhalation-solution formulation.[2]
Current clinical-development focus
Research relevant to Perforomist’s market category is concentrated in:
- Nebulized maintenance therapy for patients unable to use handheld inhalers effectively.
- Comparative effectiveness of nebulized LABAs versus long-acting muscarinic antagonists (LAMAs).
- Dual and triple therapy for moderate-to-severe COPD.
- Adherence and device usability.
- Digital nebulizer monitoring and home-based respiratory care.
- Treatment pathways for elderly patients with impaired dexterity, cognition or inspiratory flow.
Perforomist itself has limited clinical-trial differentiation. The commercial value of the product rests on established approval, dosing familiarity and access through nebulization rather than on a new clinical benefit.
What is the FDA regulatory status of Perforomist?
Perforomist remains an FDA-approved prescription drug for COPD maintenance treatment. The reference product is listed in FDA drug-labeling and product databases under formoterol fumarate inhalation solution.[1,3]
The regulatory profile is mature:
| Regulatory factor |
Assessment |
| Approval status |
Approved |
| Supplemental efficacy program |
No major active branded program identified |
| Pediatric COPD opportunity |
None of commercial significance |
| New indication opportunity |
Limited |
| Combination-product expansion |
More relevant to competitors than to legacy Perforomist |
| Regulatory risk |
Low for the approved indication |
| Commercial risk |
High because of generic and therapeutic substitution |
Perforomist is not an asthma product. FDA safety restrictions on LABA monotherapy in asthma remain relevant to formoterol-containing products. Asthma treatment generally requires an inhaled corticosteroid-containing regimen when a LABA is used.[4]
What patents protect Perforomist and when does it lose exclusivity?
Perforomist is a mature product with no meaningful remaining U.S. patent-based exclusivity comparable to a recently launched inhaled medicine. The original formoterol compound patents expired years ago, and the commercial product has faced generic competition.
Patent and exclusivity position
| Protection category |
Perforomist position |
| New chemical entity exclusivity |
Expired |
| Original compound patents |
Expired |
| FDA orphan exclusivity |
None |
| Pediatric exclusivity |
Not a material current barrier |
| Brand-specific market exclusivity |
Expired |
| Orange Book relevance |
Limited to any currently listed, unexpired patents |
| Generic substitution risk |
High |
The principal U.S. competitive barrier is no longer the active ingredient. Potential barriers relate to formulation equivalence, unit-dose packaging, manufacturing controls, nebulizer compatibility and regulatory demonstration of pharmaceutical equivalence. Those barriers can delay entry but generally do not create durable exclusivity once multiple generic manufacturers have commercial approval.
What formulations are protected?
The commercially important formulation is a sterile, unit-dose aqueous inhalation solution containing formoterol fumarate. Formulation-related protection, where applicable, would concern:
- Concentration and excipient composition
- Chemical stability
- Sterility and preservative profile
- Unit-dose vial design
- Container-closure integrity
- Manufacturing and filling processes
- Compatibility with nebulization equipment
These attributes are important for FDA approval and product quality but have weaker strategic value than composition-of-matter patents. A generic manufacturer can compete by developing an equivalent inhalation solution without reproducing every aspect of the brand’s manufacturing process.
Which companies compete with Perforomist?
Perforomist competes in two distinct markets: nebulized maintenance therapy and the broader COPD long-acting bronchodilator market.
Nebulized competitors
Relevant products and categories include:
| Product or category |
Active ingredient |
Competitive relationship |
| Generic formoterol inhalation solution |
Formoterol fumarate |
Direct substitute |
| Brovana |
Arformoterol tartrate |
Direct nebulized LABA competitor |
| Yupelri |
Revefenacin |
Once-daily nebulized LAMA competitor |
| Lonhala Magnair |
Glycopyrrolate |
Nebulized LAMA competitor |
| Nebulized budesonide combinations |
Budesonide with bronchodilator therapy |
Alternative maintenance pathway |
| Handheld LABAs |
Several agents |
Substitution risk |
| LAMA/LABA combinations |
Multiple active ingredients |
Higher-value COPD alternatives |
| Triple therapies |
ICS/LAMA/LABA combinations |
Escalation and replacement risk |
Brovana is the closest branded pharmacologic competitor because it is also a twice-daily nebulized LABA. Yupelri has a dosing advantage because it is administered once daily and belongs to the LAMA class, which is widely used in COPD maintenance therapy.
Competitive differentiation
Perforomist retains several practical advantages:
- Familiar twice-daily regimen
- Established COPD indication
- Use through a standard jet nebulizer
- Suitability for patients with poor handheld-inhaler technique
- Availability in a generic-equivalent formulation
Its disadvantages include twice-daily administration, dependence on a nebulizer, treatment time, device maintenance and limited differentiation from generic formoterol.
What is the market size and revenue outlook for Perforomist?
Public company filings generally do not disclose Perforomist revenue as a separate line item. Sales are typically included within broader respiratory, specialty or generic pharmaceutical categories. A reliable standalone brand-sales figure therefore cannot be inferred from consolidated manufacturer results.
Market structure
Perforomist participates in a mature niche rather than a high-growth drug market. Demand is driven by:
- COPD prevalence
- Growth in the elderly population
- Inability to use handheld inhalers
- Home nebulizer utilization
- Payer coverage of nebulized maintenance drugs
- Generic price competition
Demand is reduced by:
- Generic substitution
- LAMA and LABA/LAMA guideline preference
- Single-inhaler therapy
- Hospital and health-system formulary controls
- Low-cost metered-dose and dry-powder inhalers
- Limited evidence of superiority over alternatives
Five-year market projection
A reasonable base-case outlook is for low-single-digit decline in branded Perforomist revenue and flat-to-low-single-digit growth in the broader formoterol inhalation-solution category through 2029. The difference reflects generic volume growth combined with declining price and branded share.
| Scenario through 2029 |
Brand Perforomist outlook |
Generic formoterol solution outlook |
Main driver |
| Downside |
8% to 12% annual revenue decline |
Flat to 3% annual growth |
Aggressive substitution and payer pressure |
| Base case |
3% to 7% annual revenue decline |
1% to 4% annual growth |
Stable nebulizer demand with lower prices |
| Upside |
Flat to 2% annual growth |
3% to 6% annual growth |
Greater use among low-inspiratory-flow patients |
The broader nebulized COPD maintenance market can grow modestly in volume while declining in value because generic competition compresses net prices. Perforomist’s most likely commercial trajectory is stable clinical utilization with declining branded revenue.
What generic entry risks exist for Perforomist?
Generic entry risk is high because the product has an established reference standard and a mature active ingredient. FDA-approved generic formoterol fumarate inhalation solutions can replace the branded product in formularies and pharmacy channels, subject to state substitution rules and payer policy.
Generic launch scenarios
The most likely scenarios are:
- Continued generic price erosion with Perforomist retained for selected prescribers and patients.
- Formulary exclusion of the brand in favor of generic formoterol.
- Contracting based on unit-dose vial price and supply reliability.
- Partial substitution toward arformoterol or revefenacin.
- Retention of brand use where device familiarity or supply continuity matters.
Generic competitors do not need to prove a new clinical benefit. They must satisfy FDA requirements for pharmaceutical equivalence, bioequivalence or applicable product-specific requirements, quality, sterility and manufacturing consistency.[3]
Which companies are challenging Perforomist?
The principal challengers are generic manufacturers of formoterol fumarate inhalation solution and branded developers of nebulized LABA and LAMA products. The competitive threat is commercial rather than litigation-led.
Publicly reported Perforomist litigation and settlement activity has not established a major remaining patent barrier comparable to litigation involving newer inhaled combination products. Paragraph IV risk is therefore less important than the existence of approved or approvable generic alternatives and payer-driven substitution.
What patent litigation affects Perforomist?
Perforomist does not have a current high-profile patent dispute that materially changes the U.S. launch outlook. Any relevant litigation would likely concern:
- Formulation equivalence
- Manufacturing process claims
- Device or container-closure claims
- ANDA certification under Paragraph IV
- Supply or contract disputes
- Trade-name and labeling issues
For investment analysis, the absence of a durable, unexpired composition or formulation barrier means that litigation is unlikely to restore substantial brand exclusivity.
How strong is the Perforomist patent estate?
The patent estate is weak from a lifecycle-management perspective. The product has:
- An expired active-ingredient estate
- No meaningful new-chemical-entity protection
- Limited differentiation in the dosage form
- Multiple therapeutic substitutes
- High vulnerability to generic pricing
Manufacturing know-how may still have value. Sterile inhalation solutions require validated processes, controlled environments, container-closure testing and reliable supply. These factors can create operational barriers, but they do not normally support premium pricing once generic approvals are available.
How does Perforomist compare with Brovana and Yupelri?
| Attribute |
Perforomist |
Brovana |
Yupelri |
| Active ingredient |
Formoterol |
Arformoterol |
Revefenacin |
| Class |
LABA |
LABA |
LAMA |
| Nebulized dosing |
Twice daily |
Twice daily |
Once daily |
| COPD maintenance |
Approved |
Approved |
Approved |
| Direct generic pressure |
High |
Material |
Lower than mature LABAs |
| Main advantage |
Familiar formoterol profile |
Nebulized LABA alternative |
Once-daily dosing |
| Main weakness |
Generic erosion and twice-daily use |
Cost and competition |
LAMA class and product access |
Perforomist is best positioned where nebulization is clinically necessary and cost-sensitive access favors formoterol. Yupelri has a stronger convenience proposition, while Brovana is the closest branded pharmacologic comparator.
What is the commercial investment outlook for Perforomist?
Perforomist is a cash-flow maintenance asset rather than a growth platform. Its value depends on manufacturing efficiency, payer access, supply reliability and the ability to retain patients who require nebulized therapy.
The product has limited upside from new indications or clinical differentiation. Revenue exposure is more sensitive to generic share and reimbursement decisions than to trial outcomes. A buyer or licensee would likely assess:
- Net price after rebates
- Generic share
- Contract manufacturing cost
- Unit-dose vial supply
- Formulary position
- Prescriber retention
- Competitive access to nebulized LAMA products
- Remaining Orange Book-listed intellectual property
A licensing deal would be more plausible for regional commercialization, manufacturing transfer or portfolio consolidation than for a major innovation-led partnership.
Key Takeaways
- Perforomist is an FDA-approved twice-daily nebulized formoterol product for COPD maintenance therapy.
- Its pivotal clinical evidence supports sustained bronchodilation and FEV1 improvement, not a differentiated exacerbation-reduction claim.
- No major late-stage branded Perforomist clinical program drives current value.
- Original drug and product exclusivities have expired, and generic competition is the central commercial risk.
- The relevant market is mature, with volume stability but continuing price pressure.
- Brovana is the closest LABA competitor; Yupelri competes through once-daily nebulized LAMA therapy.
- Brand revenue is likely to decline through 2029, while the broader generic formoterol solution category should remain stable or grow modestly in volume.
- The patent estate is weak; manufacturing quality, sterile filling and supply reliability are more important barriers than patent rights.
- Perforomist is better viewed as a mature respiratory cash-flow product than as a clinical-development or patent-expansion opportunity.
FAQs
Is Perforomist the same as formoterol?
Perforomist is the branded formoterol fumarate inhalation solution. Generic formoterol fumarate inhalation solution contains the same active ingredient and is intended to provide an equivalent maintenance-treatment option.
Can Perforomist be used as a rescue inhaler?
No. Perforomist is not approved for acute bronchospasm. A short-acting bronchodilator is generally used for rapid symptom relief when clinically appropriate.
Is Perforomist approved for asthma?
No. Perforomist is approved for COPD maintenance treatment. LABA therapy in asthma is subject to restrictions and is generally used with an inhaled corticosteroid-containing regimen.
Does Perforomist reduce COPD exacerbations?
The principal approval evidence established maintenance bronchodilation and lung-function improvement. Perforomist is not primarily differentiated by a robust, product-specific exacerbation-reduction claim.
Is Perforomist still commercially viable after generic entry?
Yes, but its commercial viability is concentrated in patients who need nebulized maintenance therapy, prescribers who retain brand familiarity and channels where supply reliability or contracting supports continued use. Generic entry materially limits pricing power.
References
-
U.S. Food and Drug Administration. (2023). Perforomist (formoterol fumarate) inhalation solution: Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
-
National Library of Medicine. (2024). ClinicalTrials.gov: Formoterol and COPD studies. https://clinicaltrials.gov/
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
-
U.S. Food and Drug Administration. (2017). FDA requires label changes for prescription combination asthma medicines containing inhaled corticosteroids and long-acting beta-agonists. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-label-changes-certain-asthma-medicines-contained-inhaled-corticosteroids-and-long-acting-beta-agonists
